Roche is trying again and again in Alzheimer’s. This time, early data are ‘worth watching’
Years of Alzheimer’s setbacks have not dissuaded Roche from going after one of the most challenging R&D fields, and new data indicate how its continued …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
